Analisi di minimizzazione dei costi della terapia

Authors: A Matucci R Ravasio A Vultaggio E Maggi

Publish Date: 2013/02/27

Volume: 1, Issue: 1, Pages: 31-37

PDF Link

Abstract

The aim of this study was to assess the costs of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the Tuscany Health Service We conducted a CostMinimization Analysis CMA to compare the annual costs of subcutaneous immunoglobulins SCIG vs intravenous immunoglobulins IVIG We built a model in which two cohorts of patients received SCIG or IVIG The model observed the patients for 12 months and was populated using data from Careggi’s Immunoallergology Centre The model considered only direct medical costs immunoglobulin premedication infusion pump infusion materials medical staff ambulatory Sensitivity analysis on key economic parameters were performed SCIG showed the best expected cost versus IVIG of € 1519591 and € 1740889 respectively The difference in favour of SCIG € 221298 is made by lower costs both for medical staff and ambulatory This economic evaluation showed that SCIG is a costsaving strategy compared with IVIG in the treatment of patients with antibody deficiencies from the perspective of the Tuscany Health Service

Keywords: